Drug Profile
Fobrepodacin - Spero Therapeutics
Alternative Names: pVXc-486; SPR-720; VXc-100/VXc486; VXC-486 phosphateLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Spero Therapeutics
- Class Antibacterials; Antituberculars; Benzimidazoles; Fluorinated hydrocarbons; Furans; Phosphates; Pyrimidines; Urea compounds
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Nontuberculous mycobacterium infections
- No development reported Tuberculosis
Most Recent Events
- 23 Feb 2024 Spero Therapeutics completes a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT05955586)
- 18 Oct 2023 Spero Therapeutics completed a pharmacokinetics phase I trial (In volunteers) (PO) (NCT05966688)
- 01 Aug 2023 Spero Therapeutics initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT05955586)